HNF4A and diabetes mellitus: Identification of monogenic diabetes, of which there are now over 40 different genetic subtypes, have led to improved insight into the mechanism of disease and enabled precision diabetes treatment for several of these disorders, e.g., sulfonylurea agents for the treatment of KATP neonatal diabetes3,4, HNF1A-diabetes and HNF4A-diabetes5–7.